CE认证
皮肤填充剂
Revanesse Lips+ is a biocompatible, biodegradable, non-pyrogenic, sterile, injectable viscoelastic hydrogel, clear and colourless, from Prollenium Medical Technologies in Aurora, Canada, developed for lip augmentation. It is indicated for submucosal implantation in patients 22 years of age or older and is FDA approved under PMA P160042/S010. The gel carries 25 mg/mL of bioresorbable, BDDE cross-linked hyaluronic acid, produced by the Streptococcus species of bacteria, with 0.3% lidocaine and is intended for professional use. A box holds two 1.2 mL glass syringes and two 0.5 inch 30-gauge sterile needles.
*Note: This product is FDA-approved in the United States. Regulatory status and availability may vary by country. Please contact ALLPARA to confirm availability for your market.
主要优势： Revanesse Lips™+
- BDDE cross-linked hyaluronic acid 25 mg/mL with 0.3% lidocaine
- Indicated specifically for lip augmentation by submucosal implantation
- FDA approved under PMA P160042/S010
- Supplied with two 0.5 inch 30-gauge sterile needles
- Supplied as two 1.2 mL glass syringes per box
- Hyaluronic acid produced by the Streptococcus species of bacteria
- Removable label portion for the patient record
适应症与专业用途
主要适应症
- Lip augmentation by submucosal implantation
专业用途
For professional use. Revanesse Lips+ is administered by qualified physicians trained in the proper injection technique, and is not for retail sale or self-administration. It is placed by submucosal implantation in the lip using the 0.5 inch 30-gauge needles supplied. Its approval was supported by two clinical studies: a multicentre, double-blind, randomised, controlled treatment study enrolling 158 subjects over 10 months, and a multicentre, open-label retreatment study of 84 of those subjects over a further 8 months, with lip fullness assessed on the 5-point Lip Fullness Grading Scale.
治疗部位
- Lips
适用患者
Indicated for patients 22 years of age or older seeking lip augmentation. It must not be used in patients who develop hypertrophic scarring or keloid formation, in patients with evidence of scars at the intended treatment sites, in patients with acne or other inflammatory skin disease, in patients with multiple severe allergies or a history of allergy, or in patients with unattainable expectations. It must never be used in conjunction with laser, intense pulsed light, chemical peeling or dermabrasion treatments, or with over-the-counter or prescription wrinkle treatments within 4 weeks of treatment.
作用原理： Revanesse Lips™+
Lips+ is placed submucosally in the lip, where the cross-linked hyaluronic acid hydrogel adds volume directly. It is the only reference in the Revanesse range with an indication written specifically and solely for lip augmentation, which is reflected in its delivery: a fine 0.5 inch 30-gauge needle rather than the 27G used by the deeper-placed grades. The 0.3% lidocaine is present for injection comfort. Each syringe carries a removable portion of its label that can be affixed to the patient record for traceability.
为什么选择在 Allpara 订购
Allpara 提供正品、经过验证的 REVANESSE 产品，来自经过严格审核的供应商，具备完整的批次可追溯性和专家支持。我们为诊所和医美专业人士提供CE认证产品、从欧盟仓库快速配送至欧盟各地，以及具有竞争力的专业价格。我们关注的是您患者的安全、满意度和效果，并提供专属售后支持，让您安心无忧。
常见问题
How does Revanesse Lips™+ differ from the other Revanesse references?
Its indication is written solely for lip augmentation, by submucosal implantation, in patients 22 years of age or older. It shares the 25 mg/mL BDDE cross-linked hyaluronic acid and 0.3% lidocaine of Revanesse Contour™+ and Revanesse Sculpt™+, but is supplied with finer 0.5 inch 30-gauge needles rather than 27G.
What clinical evidence supports Revanesse Lips+?
Two studies formed the basis of the PMA approval decision: a multicentre, double-blind, randomised, controlled treatment study of 158 subjects lasting 10 months, and a multicentre, open-label retreatment study of 84 of those subjects lasting a further 8 months. Effectiveness was measured as change in overall Lip Fullness Grading Scale score for both lips together.
更多产品： Prollenium Medical Technologies
诊所替代选择
/ 最近浏览
继续浏览
Revanesse Lips+ is a biocompatible, biodegradable, non-pyrogenic, sterile, injectable viscoelastic hydrogel, clear and colourless, from Prollenium Medical Technologies in Aurora, Canada, developed for lip augmentation. It is indicated for submucosal implantation in patients 22 years of age or older and is FDA approved under PMA P160042/S010. The gel carries 25 mg/mL of bioresorbable, BDDE cross-linked hyaluronic acid, produced by the Streptococcus species of bacteria, with 0.3% lidocaine and is intended for professional use. A box holds two 1.2 mL glass syringes and two 0.5 inch 30-gauge sterile needles.
*Note: This product is FDA-approved in the United States. Regulatory status and availability may vary by country. Please contact ALLPARA to confirm availability for your market.
主要优势： Revanesse Lips™+
- BDDE cross-linked hyaluronic acid 25 mg/mL with 0.3% lidocaine
- Indicated specifically for lip augmentation by submucosal implantation
- FDA approved under PMA P160042/S010
- Supplied with two 0.5 inch 30-gauge sterile needles
- Supplied as two 1.2 mL glass syringes per box
- Hyaluronic acid produced by the Streptococcus species of bacteria
- Removable label portion for the patient record
适应症与专业用途
主要适应症
- Lip augmentation by submucosal implantation
专业用途
For professional use. Revanesse Lips+ is administered by qualified physicians trained in the proper injection technique, and is not for retail sale or self-administration. It is placed by submucosal implantation in the lip using the 0.5 inch 30-gauge needles supplied. Its approval was supported by two clinical studies: a multicentre, double-blind, randomised, controlled treatment study enrolling 158 subjects over 10 months, and a multicentre, open-label retreatment study of 84 of those subjects over a further 8 months, with lip fullness assessed on the 5-point Lip Fullness Grading Scale.
治疗部位
- Lips
适用患者
Indicated for patients 22 years of age or older seeking lip augmentation. It must not be used in patients who develop hypertrophic scarring or keloid formation, in patients with evidence of scars at the intended treatment sites, in patients with acne or other inflammatory skin disease, in patients with multiple severe allergies or a history of allergy, or in patients with unattainable expectations. It must never be used in conjunction with laser, intense pulsed light, chemical peeling or dermabrasion treatments, or with over-the-counter or prescription wrinkle treatments within 4 weeks of treatment.
作用原理： Revanesse Lips™+
Lips+ is placed submucosally in the lip, where the cross-linked hyaluronic acid hydrogel adds volume directly. It is the only reference in the Revanesse range with an indication written specifically and solely for lip augmentation, which is reflected in its delivery: a fine 0.5 inch 30-gauge needle rather than the 27G used by the deeper-placed grades. The 0.3% lidocaine is present for injection comfort. Each syringe carries a removable portion of its label that can be affixed to the patient record for traceability.
为什么选择在 Allpara 订购
Allpara 提供正品、经过验证的 REVANESSE 产品，具备完整的批次可追溯性、CE认证库存、欧盟范围内快速配送以及专业的售后支持。
常见问题
How does Revanesse Lips™+ differ from the other Revanesse references?
Its indication is written solely for lip augmentation, by submucosal implantation, in patients 22 years of age or older. It shares the 25 mg/mL BDDE cross-linked hyaluronic acid and 0.3% lidocaine of Revanesse Contour™+ and Revanesse Sculpt™+, but is supplied with finer 0.5 inch 30-gauge needles rather than 27G.
What clinical evidence supports Revanesse Lips+?
Two studies formed the basis of the PMA approval decision: a multicentre, double-blind, randomised, controlled treatment study of 158 subjects lasting 10 months, and a multicentre, open-label retreatment study of 84 of those subjects lasting a further 8 months. Effectiveness was measured as change in overall Lip Fullness Grading Scale score for both lips together.
更多产品： Prollenium Medical Technologies
查看制造商 →* 专业用途产品。包装可能因批次或市场而异。完整的使用说明和禁忌症请参阅随附的使用说明书。